Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 8/20 | 0.64 |
| ▸ | PDE1A | P54750 | 6/20 | 0.64 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.64 |
| ▸ | PDE2A | O00408 | 5/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120812 | 0.89 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL8051665 | 0.88 | PDE1B (0.65) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3010414 | 0.88 | PDE1B (0.65) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL8045647 | 0.85 | PDE1B (0.64) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL194641 | 0.85 | PDE1B (0.73) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3091517 | 0.84 | PDE1B (0.72) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL3666558 | 0.84 | PDE1B (0.72) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL2535845 | 0.84 | PDE1B (0.49) | PDE1BPDE1APDE1CPDE2ADPP4 | |
| SCHEMBL2537381 | 0.84 | PDE1B (0.45) | PDE1BPDE1APDE1CPDE2ADPP4 | |
| SCHEMBL8044100 | 0.83 | PDE1B (0.63) | PDE1BPDE1APDE1CPDE2APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023729-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-05-04 | — | — | EP | claimed |
| US-9255099-B2 | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-09 | — | — | US | claimed |
| US-20100173878-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-07-08 | — | — | US | claimed |
| EP-2023729-A2 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007143705-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-09-17 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-9801882-B2 | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801882-B2 | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2023729-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9255099-B2 | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150374699-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150374699-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20100173878-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173878-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173878-A1 | ORGANIC COMPOUNDS | PDE3A, PDE7A, PDE3B | PDE1B 17/4885PDE1A 15/4885PDE1C 29/4885 |
| US-20200289518-A1 | METHOD FOR TREATING BRAIN OR NERVE INJURY | GAP43, NGF, CHAT | PDE1B 1519/4885PDE1A 1787/4885PDE1C 1860/4885 |
| US-20150374699-A1 | NOVEL USES | PDE2A, PDE5A, PDE3A | PDE1B 21/4885PDE1A 13/4885PDE1C 23/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE1B 22/4885PDE1A 13/4885PDE1C 14/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE1B 17/4885PDE1A 10/4885PDE1C 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.